News
A message from Suzanne McGurn, President and CEO of CADTH
On behalf of the team at CADTH, I’m proud and excited to announce that we have launched the Canadian Journal of Health Technologies, a new open-access journal serving the Canadian and global health technology assessment (HTA) community. You can find it online at canjhealthtechnol.ca and ...
Onasemnogene abeparvovec (Zolgensma) is the first gene therapy used to treat spinal muscular atrophy — a rare progressive and life-threatening condition that often begins in childhood and is caused by a genetic mutation.
Conditions for reimbursement include a price reduction and clinical criteria for initiating treatment.
Today, CADTH recom...
More than 35 evidence reviews are mapped to the prevention, identification, treatment, and management of tuberculosis, and accessible on a digital platform
With the publication of its first condition-level review, CADTH is giving Canadian policy-makers, clinicians, and patients quick access to evidence on a range of health technologies used to ...
An initiative to advance evaluation in digital health and enhance the healthcare experience
Toronto, ON— The new Canadian Network for Digital Health Evaluation (CNDHE) is an initiative to strengthen Canadian capacity to evaluate digital health interventions. Supported with Health Canada funding, the CNDHE is led by the Centre for Digital ...
CADTH is seeking nominations for its Board of Directors and expert committees. We are currently accepting applications from individuals with significant expertise in the Canadian health care system who are interested in helping support health care decision-makers in making informed choices about health technologies.
In total, we are seeking 15 ...
